Advertisement

FDA Approves New Drug for COPD Exacerbations — Physician’s First Watch

Medical News |
March 2, 2011

FDA Approves New Drug for COPD Exacerbations

The FDA has approved roflumilast, a phosphodiesterase type 4 inhibitor, to reduce the number of exacerbations from severe chronic obstructive pulmonary disease (COPD), the agency announced on Tuesday.

Roflumilast is approved for adults with severe COPD to treat their symptoms of excess mucus and cough. It is to be taken as a daily pill. A medication guide will accompany the drug to alert patients of the risk for changes in mood, thinking, or behavior, and unexplained weight loss. Common adverse effects include diarrhea, nausea, headache, insomnia, back pain, reduced appetite, and vertigo.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement